In adult patients with newly diagnosed or suspected gastric cancer, when is diagnostic laparoscopy indicated, especially if computed tomography (CT) or positron emission tomography–computed tomography (PET-CT) findings are insufficient to determine resectability or detect peritoneal disease?

Indications for Diagnostic Laparoscopy in Gastric Cancer

Diagnostic laparoscopy with peritoneal washings should be performed in all medically fit patients with potentially resectable gastric cancer staged cT1b or higher (stage IB-III) before initiating definitive treatment. 1, 2, 3

Primary Indication: Detection of Occult Peritoneal Disease

Why CT and PET-CT Are Insufficient

• CT scanning has poor sensitivity (28-51%) for detecting peritoneal metastases despite high specificity (97-99%), missing the majority of peritoneal disease 2, 4
• FDG-PET/CT detects only 3% of occult peritoneal metastases compared to 19% detected by diagnostic laparoscopy, particularly failing in diffuse and mucinous tumor types common in gastric cancer 1, 2
• Conventional imaging misses metastatic disease in 31% of patients with potentially resectable gastric cancer that laparoscopy subsequently identifies 1, 2

Diagnostic Performance of Laparoscopy

• Diagnostic laparoscopy has 85% sensitivity and 100% specificity for detecting peritoneal metastases not found on imaging 1
• The diagnostic accuracy for determining resectability is 98.6%, preventing unnecessary laparotomies in over 40% of patients 5
• Contemporary European data show positive findings in 24.5% of patients staged as potentially curable by imaging, changing management in approximately one quarter of cases 6

Specific Clinical Scenarios Requiring Laparoscopy

Stage-Based Indications

• All stage IB-III gastric cancers (cT1b or higher) require diagnostic laparoscopy before initiating neoadjuvant therapy or proceeding to resection 1, 2, 3
• Stage T3 and/or N1 tumors identified on preoperative imaging have particularly high risk of radiographically occult metastatic disease 1

Histology-Based Risk Stratification

• Diffuse-type (Lauren classification) gastric carcinoma has the highest risk of peritoneal dissemination irrespective of cT and cN categories, making laparoscopy essential in these patients 6
• Signet-ring cell and mucinous histologies warrant laparoscopy due to the high false-negative rate of PET-CT in these subtypes 2, 3

EUS Risk Stratification (Optional Algorithm)

While NCCN recommends laparoscopy for all stage IB-III disease, EUS can refine patient selection in resource-limited settings: 1, 2

• EUS high-risk patients (T3-4, N+, or both) have a 25% yield of detecting M1 disease at laparoscopy and should undergo staging laparoscopy 7
• EUS low-risk patients (T1-2, N0) have only a 4% yield, with 96% negative predictive value for M0 disease, potentially allowing direct progression to resection 7
• However, this selective approach is not endorsed by major guidelines, which recommend universal laparoscopy for stage IB-III disease 1, 2, 3

Technical Requirements and Complementary Procedures

Mandatory Components

• Peritoneal washing cytology must be performed even when no gross disease is visible, as it provides independent prognostic information and detects occult carcinomatosis 1, 2, 4
• Targeted biopsies of suspicious lesions should be obtained during direct visualization of peritoneal surfaces 2
• Peritoneal metastases should be documented according to the Peritoneal Carcinomatosis Index (PCI) for prognostic stratification and treatment planning 2

Clinical Significance of Findings

• Positive peritoneal cytology (CY+) even without visible peritoneal implants is considered M1 disease, and surgery as initial treatment is not recommended 1, 2
• Clearing of cytology-positive disease by chemotherapy improves disease-specific survival, though cures remain rare and the role of subsequent surgery is uncertain 1
• Only 16 of 30 patients (53%) with visible peritoneal deposits had positive cytology, demonstrating that cytology and visual inspection provide complementary information 6

Common Pitfalls to Avoid

Imaging Over-Reliance

• Do not rely on PET-CT alone to exclude peritoneal disease in diffuse or signet-ring histology, as it misses 69-72% of peritoneal metastases 4
• Do not skip laparoscopy based on negative CT findings in stage IB-III disease, as CT sensitivity for peritoneal disease is only 28-51% 2, 4

Procedural Errors

• Do not omit peritoneal washings even if gross disease is visible, as cytology provides independent prognostic information 4
• Do not delay laparoscopy for serial paracentesis in patients with ascites of unknown origin, as this delays definitive diagnosis and appropriate therapy 4

Patient Selection Errors

• Do not skip laparoscopy in diffuse-type carcinoma regardless of clinical T or N stage, as this histology has the highest risk of peritoneal dissemination 6
• Laparoscopy may be avoided only in EUS low-risk patients (T1-2, N0) in highly selected circumstances, though this is not standard guideline recommendation 7

Guideline Consensus and Variations

• NCCN (2022) recommends diagnostic laparoscopy for all medically fit patients with potentially resectable stage cT1b or higher 1
• Society of Surgical Oncology (SSO) Chicago Consensus 2020 recommends strong consideration for diagnostic laparoscopy before initiation of systemic chemotherapy in all patients with proven gastric cancer 1
• Japanese Gastric Cancer Association (JGCA) recommends staging laparoscopy weakly for patients with relatively high risk of peritoneal dissemination and for advanced gastric cancer candidates for neoadjuvant chemotherapy 1
• European and Asian high-volume centers routinely incorporate diagnostic laparoscopy in staging of stage II and III tumors 1